News

European CE Mark Approval for ARCHIMEDES Biodegradable Biliary and Pancreatic Stent

Novel Biodegradable Stent Technology Approved for Sale in Europe

amg International GmbH (amg), a wholly owned subsidiary of Dublin, Ireland based Q3 Medical Devices Limited (Q3), announced that it has received CE Mark approval for the ARCHIMEDES Biodegradable Biliary and Pancreatic Stent, allowing the company to begin selling the product in Europe and other markets.

ARCHIMEDES is the only fully biodegradable biliary and pancreatic stent approved for placement in obstructed biliary or pancreatic ducts, in the world. While biliary and pancreatic duct stents are typically made of plastic or metal, amg’s ARCHIMEDES stent is made of a combination of dissolving materials permitting different rates of degradation depending on the clinical indication. The ARCHIMEDES stent is designed to completely degrade via hydrolysis in approximately 12 days, 20, days or 11 weeks, depending on its composition. The stent is designed to maintain duct patency, without occlusion as it degrades, due to its patented design. It is intended as an option to avoid repeat procedures to remove traditional non-biodegradable plastic stents, avoiding adding additional cost of care and risk for patients.

Eric K. Mangiardi, CEO of Q3 said, “The ARCHIMEDES Biodegradable Stent represents a major breakthrough in the treatment of obstructive biliary and pancreatic disorders, and also in the field of biodegradable and bioresorbable materials and their application in medical devices moving forward.” He added, “This technology has numerous benefits for patients, doctors, and healthcare providers as it has the potential to reduce complication rates typically associated with plastic stents and removal procedures.”

“This CE Mark approval is a major advancement in the treatment of obstructive biliary and pancreatic disorders and provides physicians such as myself, a truly innovative and advanced treatment option for my patients,” said Dr. Sundeep Lakhtakia of the Asian Institute of Gastroenterology in Hyderabad, India. “This is great news, as a fully biodegradable stent has the potential to reduce complication rates and procedural costs typically associated with biliary and pancreatic stenting,” Noted Dr. Paul Yeaton, Chief of Gastroenterology at the Carilion Clinic in Roanoke, VA.

In a recent safety and efficacy clinical study conducted in India and Malaysia, the ARCHIMEDES Biodegradable Biliary/Pancreatic Stent showed zero stent related complications during the study period including 53 patients.

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.
Show More

Related Articles

Leave a Reply

Close